Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immune Checkpoint Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD101 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD101 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Contains 3 Ig-like C2-type domains. |
View CD101 Products |
| Gene Delivery | CD101 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CD101 Products |
| Benchmark Ab | Anti-CD101 (Sequence of Reference mAb) Recombinant positive control. |
View CD101 Products |
| Validator | CD101 siRNA Set For knockdown verification. |
View CD101 Products |
| Related Target A | PDCD1 Synergistic immune checkpoint pathway. |
View PDCD1 Products |
| Related Target B | CTLA4 Co-inhibitory receptor for combination therapy. |
View CTLA4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Accurate Extracellular Domain Folding | HEK293 Expressed (Native Glycosylation) preserving the 3 Ig-like C2-type domains. |
| Cross-species cyno/mouse eval | Human/Mouse/Cyno ortholog proteins available with >95% purity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included. |
| False Positives | Validated siRNA included for specificity checks. |
Live CD101 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD101 therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecifics and novel immunomodulators. As an emerging inhibitory receptor, CD101 plays a critical role in immune tolerance and Treg function. As first-generation therapies reach the clinic, the next wave of R&D is targeting combination therapies with PD-1/CTLA-4 inhibitors to overcome refractory solid tumors and autoimmune conditions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Early Stage Biotech | Autoimmune Diseases | Binding Assay (Need high-purity ECD-Fc) |
| Bispecific | Emerging Pharma | Solid Tumors | Heterodimer Validation (Need Cross-reactive Abs) |
| Cell Therapy | Academic Spin-offs | Refractory Cancers | Stable Cell Line Generation (Need Lentivirus) |